Damora Therapeutics, Inc. Common Stock (DMRA) Projected to Announce Quarterly Earnings on Wednesday

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) is expected to be releasing its Q2 2026 resultson Wednesday, August 5th. Analysts expect Damora Therapeutics, Inc. Common Stock to post earnings of ($0.4470) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:00 PM ET.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). On average, analysts expect Damora Therapeutics, Inc. Common Stock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Damora Therapeutics, Inc. Common Stock Trading Down 0.1%

NASDAQ DMRA opened at $29.42 on Wednesday. The company has a market cap of $1.81 billion, a PE ratio of -5.27 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33. The stock has a 50 day moving average of $25.75 and a 200-day moving average of $25.92.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Ikarian Capital LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $6,574,000. Jain Global LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,774,000. Remedium Capital Partners LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,772,000. Boothbay Fund Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $2,204,000. Finally, Connective Capital Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $100,000. 14.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on DMRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Wedbush reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. TD Cowen initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday. They set a “buy” rating and a $50.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $43.38.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.